Generated by AI
Summary of Nov 3's posts. Generated by AI.
Summary of Jul 13's posts. Generated by AI.
No summary yet.
Summary of Nov 3's posts. Generated by AI.
Investors talking about NMRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Neumora Therapeutics, Inc. Common Stock represents Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. The company applies a precision medicine approach that combines neuroscience, biological insight, and data science to identify and advance therapies aimed at central nervous system targets. Its current pipeline includes candidate medicines in clinical and preclinical development for major depressive disorder, agitation associated with dementia, schizophrenia, Parkinson’s disease, ALS, and obesity-related metabolic disease. Neumora Therapeutics is positioned within the biotechnology sector as a research-driven company centered on novel mechanisms of action for underserved neurological and psychiatric disorders. The common stock reflects the market’s view of a company whose value is tied to progress across this specialized drug development pipeline and the broader demand for new CNS therapies.
Website260 Arsenal Place
Watertown, MA, 02472
United States
The latest articles about NMRA.